Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ultra-Safe Hormonal Strategy: Transdermal Estradiol Added to Progestins for Endometriosis
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Summary
Endometriosis is a chronic, estrogen-dependent disease affecting women of reproductive age, associated with pelvic pain, infertility, and reduced quality of life. Progestins are the standard first-line therapy, but long-term treatment requires well-tolerated regimens that balance efficacy with patient satisfaction. This study will compare two combinations of progestins with natural transdermal estradiol-dienogest versus drospirenone-to evaluate which regimen provides greater patient satisfaction after 6 months of therapy.
Official title: Transdermally Applied Estradiol Delivery In Ultra-Safe Medications Valuable In Treatment Against Endometriosis
Key Details
Gender
FEMALE
Age Range
18 Years - 40 Years
Study Type
OBSERVATIONAL
Enrollment
138
Start Date
2025-08-11
Completion Date
2026-02
Last Updated
2025-10-02
Healthy Volunteers
No
Conditions
Interventions
Drospirenone 4 mg orally
Daily oral administration of Drospirenone 4 mg + Transdermal estradiol; continuous administration for at least 6 months.
Dienogest 2 mg orally
Daily oral administration of Dienogest 2 mg + Transdermal estradiol; continuous administration for at least 6 months.
Locations (1)
Gynecology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy